Landos Biopharma, Inc.

30 articles with Landos Biopharma, Inc.

• Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

  4/13/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced the appointment of Tiago Girão to its Board of Directors.

• Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

  4/6/2021

  Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for omilancor (BT-11),

• Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

  2/23/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 12:00 PM EST.

• 

  Money on the Move: February 3-9

  2/10/2021

  The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
• 

  Life Sciences Companies Ringing the Nasdaq Bell this Week

  2/4/2021

  Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.

• Landos Biopharma Announces Pricing of Initial Public Offering

  2/4/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million

• 

  Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?

  1/14/2021

  On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.

• Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel DiseaseNX-13 is the Company’s second first-in-class candidate to begin clinical development

  7/14/2020

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune disease, announced that the first patient has been dosed in a Phase 1 study of NX-13, the Company’s novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease.

• Landos Biopharma to Present at Two Upcoming Investor Conferences

  5/12/2020

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer of Landos, will present at the following upcoming investor conferences. Presentation Details: Event: UBS Virtual Global Healthcare Conference  Date:  Tuesday, May 19, 2020 Time: 1:

• Landos Biopharma to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

  3/24/2020

  Landos Biopharma, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer, plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Investor Conference.

• Landos Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference

  2/26/2020

  BLACKSBURG, Va., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present a company overview at the Cowen and Company 40 th Annual Health Care Conference. The presentation will take place on Monday, March 2, 2020, at 10:30 a.m. EST at the Boston Marrio

• Landos Biopharma to Present at the Annual BIO CEO & Investor Conference

  2/6/2020

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President, and Chief Executive Officer, will present a company overview at the Annual BIO CEO & Investor Conference

• Landos Biopharma to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  Landos Biopharma announced that Dr. Josep Bassaganya-Riera, Chairman, President, and Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

• Landos Biopharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

  11/26/2019

  Landos Biopharma announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conference in New York.

• 

  Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  11/19/2019

  Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.

• Landos Biopharma to Present at Upcoming Conferences in 2019

  10/15/2019

  Landos Biopharma announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conferences.

• 

  Clinical Catch-up for August 19-23

  8/26/2019

  Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.

• Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis

  8/20/2019

  Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with mild to moderate ulcerative colitis

• 

  IBD-Focused Landos Biopharma Secures $60 Million in Financing

  8/14/2019

  Landos said the funds will be used to advance its lead asset, BT-11, into global Phase II clinical trials for ulcerative colitis and Crohn’s disease.

• Landos Biopharma Completes $60 Million Series B Financing

  8/13/2019

  RTW Investments joins existing investor Perceptive Advisors in leading financing with a strong syndicate